FDA’s Digital Health Center of Excellence: What Medical Device Brands Need to Know
- 2 days ago
- 4 min read
The FDA’s Digital Health Center of Excellence (DHCoE) is rapidly becoming a central piece of the regulatory landscape for digital health technologies within the medical device world. If your company develops software as a medical device, connected health tools, AI/ML-enabled systems, or other digital health technologies, you need to understand what DHCoE means and how it may impact your regulatory strategy.
Whether you are designing your next-generation device or preparing for a submission, this update should be on your radar.
What Is the DHCoE and Why It Matters
The DHCoE is part of the FDA’s Center for Devices and Radiological Health (CDRH). It was created to centralize and coordinate digital health expertise across the agency and serve as a resource hub for stakeholders working at the intersection of software, data, and medical technology.
It does not replace traditional regulatory pathways, but it does signal a bigger commitment by FDA to streamline regulatory science, policy development, and stakeholder engagement in digital health.
The center’s mission touches multiple areas that matter to your business, including:
Regulatory science support. DHCoE provides policy and technology support that helps both FDA reviewers and industry understand how digital health technologies should be evaluated.
Advanced technology expertise and training. DHCoE consolidates specialized knowledge in emerging areas like cybersecurity, AI/ML, and real-world evidence.
Stakeholder collaboration and partnerships. The center fosters strategic partnerships, bringing manufacturers, tech developers, clinicians, and regulators together to align on best practices.
This combination of regulatory science, expertise, and collaborative networks gives medical device companies a more consistent and structured environment to navigate digital product development safely and efficiently.
What Digital Health Really Means for Devices
“Digital health” isn’t a buzzword. For regulatory purposes, it covers a spectrum of technologies such as mobile medical apps, wearable medical devices, connected sensors, software as a medical device (SaMD), and machine learning algorithms that are intended for use in healthcare settings.
That means your next software release may be regulated as a medical device if it meets the statutory definition, even if the hardware it runs on isn’t what people traditionally think of as a device. This has regulatory impact — including classification, premarket submission expectations, and post-market obligations — so understanding the regulatory frame early is essential.
Why DHCoE Helps But Doesn’t Replace Submission Strategy
Some teams mistakenly think DHCoE replaces traditional paths like 510(k), De Novo, or PMA for digital health products. It does not.
DHCoE supports regulatory review. The center enhances internal FDA coordination for digital health, but it is not the agency’s approval authority. Decisions about clearance or approval still reside with existing regulatory units.
You still must define your intended use and risk category. Whether a software feature is Class I exempt or a higher risk SaMD determines your pathway and evidence requirements. DHCoE may inform guidance development, but your submission strategy drives the outcome.
FDA guidances with digital health content are expanding. The DHCoE maintains and develops guidance documents that clarify expectations around digital components, cybersecurity, interoperability, and AI/ML considerations. Leveraging these resources can reduce regulatory uncertainty.
Opportunities for Innovators
The DHCoE’s presence means the FDA recognizes digital health technologies as a core component of medical innovation. Companies that align early with regulatory science priorities and clarity from the center can:
Speed product development by reducing guesswork on regulatory expectations
Leverage tools like the FDA’s Digital Health Policy Navigator and FAQ resources (which consolidate policy threads in one place) to assess regulatory applicability early in design cycles
Access emerging guidance on AI/ML, cybersecurity, and connected health integration
This matters for customer confidence, payer adoption, and long-term product lifecycle planning.
Practical Steps for Medical Device Brands
Whether you are an established manufacturer or a startup scaling your first digital product, here’s a compliance playbook that follows FDA’s regulatory environment:
1. Define your intended use clearly. Regulatory status hinges on how the device is intended to be used in clinical care.
2. Engage early with FDA resources. Use DHCoE materials, digital health guidance, and interactive tools to reduce regulatory risk.
3. Apply risk-based planning. Software and digital health features add layers of cybersecurity, data handling, and updating requirements. Build those into your Quality Management System and design controls early.
4. Review applicable guidance. The FDA’s library of digital health guidance is growing. Staying current prevents surprises.
5. Prepare for real-world evidence expectations. Many digital devices are expected to demonstrate safety and performance beyond premarket testing.
Bottom Line
FDA’s Digital Health Center of Excellence reflects how seriously regulators now treat digital health technologies. It is not a separate approval gate, but a strategic resource designed to help both industry and FDA speak the same language about innovation, safety, and risk. If your product roadmap includes connected health, machine learning, or software-driven functionality, building your regulatory strategy in partnership with compliance experts is no longer optional.
Bustos Law Group helps medical device brands navigate digital health regulatory strategy from submission planning through post-market compliance so you can innovate with confidence and stay ahead of FDA expectations.
Comments